EGFR and neoplasm: The neighboring non-resistant cells can take up these exosomes and positively regulate mTOR and epithelial growth factor receptor (EGFR) signaling pathways to enhance the glycolysis and promote EpCAM+ tumor cells to ovarian cancer stem cells (CD133+ and CD117+CD44+) and putative drug-resistant tumor cell phenotype (EpCAM+ CD45+) transformation [152, 155, 159–162].